More search options
Basket icon
No items
Basket icon

Product details

By continuing to use our site you consent to the use of cookies as described in our privacy policy unless you have disabled them.
You can change your cookie settings at any time but parts of our site will not function correctly without them.
Case
-
Reference no. 9-391-050
Subject category: Ethics and Social Responsibility
Authors: Joseph L Badaracco (Harvard Business School); Christopher Sturr (Harvard Business School)
Published by: Harvard Business Publishing
Originally published in: 1990
Version: 1 April 1991
Length: 12 pages
Data source: Published sources
Topics: Business government relations; Ethics; Women
Share a link: https://casecent.re/p/46868
| No reviews for this item
This product has not been used yet
View our pricing guide or login to see prices.

Abstract

Describes the factors faced by Roussel UCLAF, a French drug company, in deciding whether and how to market a controversial new drug, RU 486, which is often called ''the French abortion pill''. Roussel''s decision involved its relations with the French government, its parent company, the German chemicals giant Hoechst, supporters and opponents of abortion rights in France and the United States, and the research community. The objective is to show students the complex web of responsibilities managers face and the practical issues that arise from conflicts among those obligations.
Location:
France, United States
Industry:
Pharmaceutical
Size:
Large, USD2 billion revenues
Other setting(s):
1988
Teaching note
-
Reference no. 5-392-147
Subject category: Ethics and Social Responsibility
Authors: Joseph L Badaracco (Harvard Business School); Allen Webb (Harvard Business School)
Published by: Harvard Business Publishing
Originally published in: 1992
Version: 15 May 1992
Length: 13 pages
Data source: Published sources
View full details
Compact case
Supplement
-
Reference no. 9-391-051
Subject category: Ethics and Social Responsibility
Authors: Joseph L Badaracco (Harvard Business School); Christopher Sturr (Harvard Business School)
Published by: Harvard Business Publishing
Originally published in: 1990
Version: 26 March 1991
Length: 2 pages
Data source: Published sources
Topics: Business government relations; Ethics; Women
View full details

About

Abstract

Describes the factors faced by Roussel UCLAF, a French drug company, in deciding whether and how to market a controversial new drug, RU 486, which is often called ''the French abortion pill''. Roussel''s decision involved its relations with the French government, its parent company, the German chemicals giant Hoechst, supporters and opponents of abortion rights in France and the United States, and the research community. The objective is to show students the complex web of responsibilities managers face and the practical issues that arise from conflicts among those obligations.

Settings

Location:
France, United States
Industry:
Pharmaceutical
Size:
Large, USD2 billion revenues
Other setting(s):
1988

Related

Teaching note
-
Reference no. 5-392-147
Subject category: Ethics and Social Responsibility
Authors: Joseph L Badaracco (Harvard Business School); Allen Webb (Harvard Business School)
Published by: Harvard Business Publishing
Originally published in: 1992
Version: 15 May 1992
Length: 13 pages
Data source: Published sources
View full details
Compact case
Supplement
-
Reference no. 9-391-051
Subject category: Ethics and Social Responsibility
Authors: Joseph L Badaracco (Harvard Business School); Christopher Sturr (Harvard Business School)
Published by: Harvard Business Publishing
Originally published in: 1990
Version: 26 March 1991
Length: 2 pages
Data source: Published sources
Topics: Business government relations; Ethics; Women
View full details